Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14454779 | 0.89 | MCHR1 (1.00) | MCHR1SLC2A1 | |
| SCHEMBL5582724 | 0.83 | MCHR1 (0.79) | MCHR1 | |
| SCHEMBL5582975 | 0.83 | MCHR1 (0.89) | MCHR1SLC2A1 | |
| SCHEMBL5582648 | 0.83 | MCHR1 (0.81) | MCHR1 | |
| SCHEMBL14454797 | 0.81 | MCHR1 (1.00) | MCHR1SLC2A1 | |
| SCHEMBL5582998 | 0.80 | MCHR1 (0.84) | MCHR1SLC2A1 | |
| SCHEMBL5583097 | 0.80 | MCHR1 (0.84) | MCHR1SLC2A1 | |
| SCHEMBL14454795 | 0.80 | MCHR1 (0.82) | MCHR1SLC2A1 | |
| SCHEMBL14454794 | 0.80 | MCHR1 (1.00) | MCHR1 | |
| SCHEMBL4621859 | 0.80 | MCHR1 (1.00) | MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7956049-B2 | Melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-07 | — | — | US | disclosed |
| US-20090221548-A1 | MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-09-03 | — | — | US | disclosed |
| US-7553836-B2 | 7-(4-Chlorophenyl)-2-(3-methoxy-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one trifluoroacetic acid salt; obesity; antidiabetic agents; antidepressants; anxiolytic agents; combination with antipsychotic drugs enhanced therayp for schizophrenic disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-30 | — | — | US | disclosed |
| EP-1987039-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | Brystol-Myers Squibb Company (US) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007092416-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-16 | — | — | WO | disclosed |
| US-20070185097-A1 | MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221548-A1 | MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | MCHR1, MCHR2, MC1R | MCHR1 1/4885SLC2A1 540/4885 |
| US-20070185097-A1 | MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | MCHR1, MCHR2, MC1R | MCHR1 1/4885SLC2A1 540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.